Mankind Pharma, QIP

Mankind Pharma raises Rs 3,000 crore via QIP, shares react
Shares of Mankind Pharma Ltd were trading in the red today even as the pharma firm said its board has approved the closure of the issue for the qualified institutions placement (QIP) of equity shares of the company on Thursday,
Mankind Pharma’s board approves QIP of equity shares to raise ₹3,000 crore
The equity shares will be allotted to the eligible QIBs at an issue price of ₹2,520 per share - a price which includes a premium of ₹ 2,519 per piece, aggregating to a sum of ₹2,999.99 crore.
Mankind Pharma Secures ₹3,000 Crore via QIP for Growth
In a meeting held on December 20, 2024, the Fund Raising Committee of the company had approved the issue of 1.19 crore equity shares to QIB
Mankind Pharma raises nearly Rs 3,000 crore from eligible institutional buyers via QIP issue
Mankind Pharma said that its board has approved the closure of the issue for the qualified institutions placement of equity shares of the company on Thursday, 19 December 2024.
Mankind Pharma Approves Share Sale Worth Rs 3,000 Crore To Institutions To Pare Debt
Mankind Pharma aims to become a debt-free company within the next three years, top executive told NDTV Profit earlier.
Mankind Pharma to launch up to Rs 3,000-crore QIP shortly
The proposed capital raise is part of Mankind Pharma's plan to fund the Rs 13,630-crore acquisition of private equity firm Advent International-owned Bharat Serums and Vaccines (BSV) announced in July
Mankind Pharma allots 1.19 cr equity shares under QIP issue
Consequent to the aforesaid allotment, the paid-up share capital of the Company has increased from Rs 40,06,62,138 consisting 40,06,62,138 equity shares to Rs 41,25,66,899 consisting 412566899 equity shares having face value of Re.
Mankind Pharma to raise ₹3,000 cr via QIP to fund acquisition of Bharat Serums; stock rises 2%
The pharma company has acquired 100% stake in BSV for ₹13,768 crore, to be funded through a combination of internal accruals and external debt.
Mankind Pharma set to launch QIP to raise Rs 3,000 crore: sources
The indicative issue price for the QIP is expected to be approximately ₹2,520 per share, which could lead to an equity dilution of 2.9% on a post-issue basis, sources added.
Mankind Pharma Share Price In Focus Following Launch Of Rs 3,000 Crore QIP For BSV Acquisition; BUY?
Mankind Pharma, India’s fourth-largest pharmaceutical company by domestic sales, has officially launched its Rs 3,000 crore Qualified Institutional Placement (QIP) to partly fund the acquisition of Bharat Serums and Vaccines (BSV),
Mankind Pharma launches Rs 3,000 crore QIP to fund Bharat Serums acquisition; floor price set at Rs 2,616.55
The QIP opened on December 16, 2024, with Mankind Pharma keeping the option to offer a discount of up to 5% on the floor ...
Stock market update: Nifty Pharma index 0.86%
Benchmark NSE Nifty50 index ended down 364.21 points at 23587.5, while the BSE Sensex stood 1176.46 points at 78041.59. Among ...
HDFC Bank, IPCA Labs, Mankind Pharma: How to trade these 3 buzzing stocks
An analyst from YES Securities said that Ipca Labs has failed to break out of its falling trendline and has formed a bearish ...